Stocks
Intra-Cellular Therapies (ITCI) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | 2.72 | -64.1 | 2.17 | 3.03 | 8.43 | 8.47 | |||
| Changes by years, y/y, % | +108% | -2 455% | -103% | +39% | +178% | +45.2% | |||
Intra-Cellular Therapies. Debt/EBITDA
Intra-Cellular Therapies. Debt/EBITDA, changes, %
Intra-Cellular Therapies (ITCI) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q4 | LTM ? | |||
| Debt/EBITDA | 3.03 | 3.51 | 8.99 | 8.17 | 8.47 | 8.47 | ||
| Changes by years, y/y, % | +39% | +61% | +260% | +196% | +180% | |||
| Changes by quarters, q/q, % | +10% | +16% | +156% | -9% | +4% | |||
